NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.06 -0.74 (-0.93%) GOLD FUTURES
2,423.10 -15.40 (-0.63%) DOW
39,826.74 +19.97 (+0.05%) Bitcoin GBP
54,814.19 +744.95 (+1.38%)
Century Therapeutics, Inc. (IPSC)
- GuruFocus.com
Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...
Comprehensive Analysis of Financial Performance and Strategic Milestones
- GlobeNewswire
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK mediated rejection in allogeneic cell therapies PHILADELPHIA, May 10, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developi
- Zacks
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 10% and 185%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
